

Influenza Antivirals: Efficacy and Resistance

Tuesday 8th - Thursday 10th November 2011
Rio Othon Palace Hotel, Rio de Janeiro, Brazil

Preliminary Programme

Tuesday 8 th November	
07.00 onwards	Registration
09.30-10.00	Opening – President of Fiocruz and/or representative of MOH Co-chairs: <i>Marilda Siqueira, Otavio Oliva, Alan Hay</i>
10.00-10.30	Introductory Keynote Lecture Chair: <i>Otavio Oliva (USA)</i> <ul style="list-style-type: none"> Influenza and its control by vaccines and drugs <i>Arnold Monto (USA)</i>
10.30-11.00	Coffee
11.00-13.00	Symposium Session 1: Influenza Antivirals (current status) Co-chairs: <i>Alan Hay (UK), Marilda Siqueira (Brazil)</i> <ul style="list-style-type: none"> Efficacy/effectiveness <i>Jonathan Van Tam (UK)</i> Clinical use – therapy and prophylaxis (recommendations) <i>Michael Ison (USA)</i> Antiviral action and basis of resistance <i>Jenny McKimm-Breschkin (Australia)</i> Recent developments (including drug combinations) <i>Frederick Hayden (USA)</i>
13.00-14.30	Lunch
14.30-16.00	Concurrent Workshops 1 <ol style="list-style-type: none"> Use/effectiveness of antivirals – national policies/guidance Co-chairs: <i>Charles Penn (Switzerland), tbc</i> Surveillance/monitoring of resistance Co-chairs: <i>Alexander Klimov (USA), Rodrigo Fasce (Chile)</i>
16.00-16.30	Tea/Coffee
16.30-18.30	Demonstrations and Posters Practical demonstrations/discussions: <ul style="list-style-type: none"> Standard resistant viruses – characteristics and availability <i>Aeron Hurt (Australia)</i> Analysis of resistance data – IC₅₀ determination/statistical analyses <i>Catherine Macken (USA) & Angie Lackenby (UK)</i> Databases for collation and sharing of antiviral resistance data <ul style="list-style-type: none"> Tessy database of antiviral resistance <i>Adam Meijer (The Netherlands)</i> South American antiviral resistance database <i>Paul Agapow (UK)</i> GISAID EpiFlu sequence database <i>Mia Brytting (Sweden)</i>

Influenza Antivirals: Efficacy and Resistance

Tuesday 8th - Thursday 10th November 2011

Rio Othon Palace Hotel, Rio de Janeiro, Brazil

Wednesday 9th November	
08.30-10.30	<p>Symposium Session 2: Development of resistance Co-chairs: <i>Masato Tashiro (Japan), Vilma Savy (Argentina)</i></p> <ul style="list-style-type: none"> • Surveillance of resistance emergence <i>Maria Zambon (UK)</i> • Assays for monitoring susceptibility/resistance <i>Larisa Gubareva (USA)</i> • Consequences of resistance – <i>in vitro</i> fitness; <i>in vivo</i> infectivity/transmissibility <i>Elena Govorkova (USA)</i> • Regulatory issues relating to licensure and antiviral resistance (Exact title TBC) <i>Charles Penn (Switzerland)</i>
10.30-11.00:	Coffee
11.00-12.30	<p>Concurrent Workshops 2</p> <p>a. Clinical use – different regimens/patient groups Co-chairs: <i>Norio Sugaya (Japan), Pablo Bonvehi (Argentina)</i></p> <p>b. Assays of resistance (enzyme and cell culture) Co-chairs: <i>Sylvie van der Werf (France), Andrea Pontoriero (Argentina)</i></p>
12.30-14.00	Lunch
14.00-15.00	Demonstrations and Posters
15.00-19.00	Tour of Fiocruz and Castle (optional)
Thursday 10th November	
9.00-10.30	<p>Concurrent Workshops 3</p> <p>a. Novel mechanisms of inhibition and resistance Co-chairs: <i>Jenny McKimm-Breschkin (Australia), Thiago Souza (Brazil)</i></p> <p>b. Molecular detection and effects of 'resistance' mutations Co-chairs: <i>Guy Boivin (Canada), Nancy Bellei (Brazil)</i></p>
10.30-11.00	Coffee
11.00-13.00	<p>Symposium Session 3: Current and future perspectives Co-chairs: <i>Celia Alpuche (Mexico), tbc</i></p> <ul style="list-style-type: none"> • Modelling of antiviral use and resistance emergence - implications for use • <i>Dennis Chao (USA)</i> • Antivirals: 'novel' inhibitors/targets <i>Robert Krug (USA)</i> • Antivirals in seasonal and pandemic flu- future perspectives <i>Rick Bright (USA)</i>
13.00	Conclusions and close of meeting